Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
58.55%
Operating Margin
57.42%
Net Margin
51.92%
Efficiency Metrics
Revenue per Expense Ratio
2.35
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
69.45%
Income Tax Rate
0.69%
EPS
11.3500000000
Balance Sheet Analysis
Current Ratio
2.38
Cash Ratio
0.95
Working Capital
$269.41M
Debt to Equity
0.43
Debt to Assets
29.52%
Equity Ratio
68.08%
Cash Flow Analysis
Operating Cash Flow Ratio
64.23%
Free Cash Flow Ratio
44.95%
CapEx to Revenue
19.28%
Dividends Paid
$308.15M
Stock Buybacks
$13.95M
Total Shareholder Returns
$322.10M
Cash Position Change
-47.99%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 344.85%
Detailed Growth Metrics
Core Performance
Revenue
23.95%
Net Income
43.45%
EPS
44.40%
Operating Income
38.81%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
2.42%
Operating Cash Flow
139.19%
Free Cash Flow
181.55%
Balance Sheet Health
Assets
-3.58%
Debt
-30.72%
Book Value per Share
16.34%
Inventory
150.28%
Shareholder Returns
Dividends per Share
344.85%
Shares Outstanding
-0.82%
Long Term Trends
3Y Revenue/Share
47.25%
5Y Revenue/Share
135.83%
3Y Dividend/Share
2,536.75%
5Y Dividend/Share
0.00%